Molecular Partners AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MLLCF research report →
About the company
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers.
- CEO
- Patrick Amstutz
- IPO
- 2018
- Employees
- 142
- HQ
- Schlieren, BC, CH
Price Chart
- Market Cap
- $135.04M
- P/E
- -2.04
- P/S
- 0.00
- P/B
- 1.74
- EV/EBITDA
- -0.78
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -66.19%
- ROIC
- -69.14%
- Revenue
- $0 · -100.00%
- Net Income
- $-61,680,555 · -14.13%
- EPS
- $-1.65 · -1.23%
- Op Income
- $-55,461,576
- FCF YoY
- 16.18%
- 52W High
- $4.85
- 52W Low
- $2.25
- 50D MA
- $3.49
- 200D MA
- $3.20
- Beta
- 0.67
- Avg Volume
- 40
Get TickerSpark's AI analysis on MLLCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MLLCF coverage
Recent articles, reports, and earnings notes.
No research on MLLCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MLLCF report →Similar companies
Peers in the same neighborhood.